Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Nuplazid — Revenue

Other product segments

Daybue
$101.14M+19.6%

Similar metrics at other companies

Catalyst Pharmaceutical logo
CPRXProduct Revenue Net — Revenue
$149.34M+5.6%
PTC Therapeutics logo
PTCTProduct — Revenue
$225.57M+47.0%
Jazz Pharmaceuticals logo
JAZZProduct sales, net — Revenue from Contract with Customer, Excluding Assessed Tax
$1.03B+22.1%
Lantheus Holdings logo
LNTHPYLARIFY — Revenue
$240.92M-6.5%
Axsome Therapeutics logo
AXSMProduct — Revenue
$189.4M+57.4%
Alkermes logo
ALKSProduct — Revenue
$338.11M+38.3%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.7B+37.0%
Enterprise value$3.47B+36.6%
P/E9.9×-2.0×
P/S3.4×+0.7×

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's nuplazid — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's nuplazid — revenue?
Acadia Pharmaceuticals (ACAD) reported nuplazid — revenue of $166.92M in Q1 2026.
How has Acadia Pharmaceuticals's nuplazid — revenue changed year-over-year?
Acadia Pharmaceuticals's nuplazid — revenue increased by 4.5% year-over-year, from $159.72M to $166.92M.
What is the long-term trend for Acadia Pharmaceuticals's nuplazid — revenue?
Over 3 years (2022 to 2025), Acadia Pharmaceuticals's nuplazid — revenue has grown at a 9.6% compound annual growth rate (CAGR), from $517.24M to $680.09M.
What does nuplazid — revenue mean?
This metric represents the total net sales generated from the commercialization of a specific pharmaceutical product, excluding any taxes collected from customers. It serves as a primary indicator of the product's market adoption, pricing power, and overall commercial performance within the company's portfolio. Tracking this revenue stream helps investors evaluate the growth trajectory and lifecycle maturity of the therapeutic asset.